Hematopoietic Stem Cell Transplantation (HSCT) Market Forecasts to 2030 – Global Analysis By Transplant Type (Allogeneic, Autologous and Other Transplant Types), By Disease Indication (Lymphoproliferative Disorders, Non-malignant Disorders, Leukemia and O

Hematopoietic Stem Cell Transplantation (HSCT) Market Forecasts to 2030 – Global Analysis By Transplant Type (Allogeneic, Autologous and Other Transplant Types), By Disease Indication (Lymphoproliferative Disorders, Non-malignant Disorders, Leukemia and Other Disease Indications), Application (Bone Marrow Transplant (BMT), Peripheral Blood Stem Cells Transplant (PBSCT), Cord Blood Transplant (CBT) and Other Applications), End User and By Geography

According to Stratistics MRC, the Global Hematopoietic Stem Cell Transplantation (HSCT) Market is accounted for $2.89 billion in 2023 and is expected to reach $6.12 billion by 2030 growing at a CAGR of 11.3% during the forecast period. Hematopoietic stem cells are transplanted into a patient during a medical procedure known as hematopoietic stem cell transplantation (HSCT), also referred to as bone marrow transplantation, in order to replace or repair their damaged or dysfunctional bone marrow. Red blood cells, white blood cells, and platelets can all be produced by hematopoietic stem cells, which are multipotent cells with this special ability.

According to the data published by the Leukemia & Lymphoma Society (LLS) in 2021, around 61,090 people were estimated to be diagnosed with leukemia 2021.

Market Dynamics

Driver

Increasing prevalence of cancer

Due to the demand for cutting-edge treatment options, the rising incidence of cancer is a significant market driver for hematopoietic stem cell transplantation (HSCT). For patients with different types of blood cancers and hematological disorders, HSCT is an essential treatment. Cancer incidence increases along with the demand for HSCT procedures, which propels market growth. This procedure involves swapping out unhealthy stem cells for damaged or cancerous blood-forming cells, potentially curing some forms of cancer. As a result, the growing number of cancer patients is a major factor in boosting the market for HSCT and stimulating research and development in the area.

Restraint

Expensive transplantation procedures

The costs associated with the entire transplant procedure, including pre-transplant assessments, the transplant procedure itself, and post-transplant care, can be exorbitant. For a sizeable portion of the population, this financial burden frequently restricts accessibility, which has an effect on the acceptance of HSCT as a treatment option. Additionally, it creates difficulties for insurance companies and healthcare systems, which prevents HSCT from being used and adopted more widely. As a result, the market is significantly constrained by the high cost of hematopoietic stem cell transplantation (HSCT) procedures.

Opportunity

Investment in healthcare sector

Due to the rising investment in the healthcare industry, the hematopoietic stem cell transplantation market has a sizable opportunity. The government sector in many regions also contributes money and investments to advance the local healthcare system. In order to support research in stem cell therapy and regenerative medicine, the National Institutes of Health (NIH) announced a grant worth USD 29 million in 2019. The grant was given to US researchers that are using stem cells to create novel treatments for a number of diseases. It ensures that more patients can benefit from this life-saving therapy is created by increased investment, which also supports the development of specialized transplant centers, improves access to cutting-edge care, and fosters innovation.

Threat

Adverse impacts of hematopoietic stem cell transplantation

The negative effects of hematopoietic stem cell transplantation on organs and body parts, including the gastrointestinal system, mouth, heart, and lungs, associated with the conditioning regimen and others, as well as the serious complication of graft vs. host disease, are anticipated to hinder the market's expansion. Both regular allogeneic stem cell transplants and reduced-intensity allogeneic stem cell transplants can result in graft-versus-host disease (GVHD), in which the graft mistakes the patient's healthy cells (the host) for foreign invaders and attacks and destroys them. Moreover, even a close HLA match between the patient and donor lowers but does not completely eliminate the risk of GVHD. It might even be fatal in some circumstances. As a result of such events, the market is expected to decline.

Covid-19 Impact

The hematopoietic stem cell transplantation (HSCT) market was significantly impacted by the COVID-19 pandemic. Due to the allocation of healthcare resources, it initially disrupted transplant schedules, potentially delaying life-saving procedures. However, the crisis highlighted the significance of medical innovation and research, potentially spurring more funding and interest in HSCT as a cutting-edge therapy. Logistics were impacted by supply chain disruptions that reduced the supply of vital transplant supplies. Telemedicine has become more popular for pre- and post-transplant care as well. The long-term effects of the pandemic may require adjustments to ensure the safety of immunosuppressed patients, which could potentially reshape the market.

The autologous segment is expected to be the largest during the forecast period

During the anticipated period, the market for hematopoietic stem cell transplantation is anticipated to be dominated by the autologous transplantation segment. Following purification procedures, autologous bone marrow products are taken from the patient and reinfused. Allogeneic transplant recipients in the US exceeded 8,000 per year in 2013, and 9,498 transplants are anticipated in 2019, up from 9,509 in 2018, according to the Center for International Blood and Marrow Transplant Research's (CIBMTR) 2020 report. Since 2000, the number of autologous transplant recipients in the US has increased steadily, reaching 14,270 in 2019. Over 60% of transplant activity in the US still involves autologous transplants. All of these factors contribute to the segment expansion.

The bone marrow transplant (BMT) segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the bone marrow transplant segment is anticipated to grow at a rapid pace. In order to replace bone marrow that does not produce enough healthy blood cells, healthy blood-forming stem cells are injected into the body during a bone marrow transplant procedure. Patients with dysfunctional or depleted bone marrow can receive healthy hematopoietic stem cells through a bone marrow transplant. Growth in the segment is anticipated to be boosted by rising research and development efforts. Additionally, it is anticipated that rising supportive actions by the public and private sectors toward bone marrow transplants will spur segment growth.

Region with largest share

The market for hematopoietic stem cell transplantation (HSCT) in North America is expected to witness significant market share. The region is being driven primarily by factors like the rise in leukemia cases and rising public and private sector investment in research and development. Leukemia accounted for 3.2% of all new cancer cases and 3.9% of all cancer deaths in the US in 2020, according to data from the National Cancer Institute. For instance, the National Eye Institute's researchers began a clinical trial in December 2019 to examine the safety of a novel patient-specific stem cell-based therapy for the treatment of geographic atrophy. Therefore, it is anticipated that rising leukemia cases will increase demand for hematopoietic stem cell transplantation, driving up market growth in the area.

Region with highest CAGR

Due to a number of crucial factors, the hematopoietic stem cell transplantation (HSCT) market in the Asia-Pacific region is expanding rapidly. The demand for HSCT procedures is being driven by the rising geriatric population and the prevalence of hematological disorders. The region is becoming a hub for HSCT as a result of improvements in healthcare infrastructure and medical tourism in nations like India, China, and South Korea. Furthermore, Asia Pacific is a promising market for HSCT services and technologies due to collaborations with international healthcare providers and research organizations.

Key players in the market

Some of the key players in Hematopoietic Stem Cell Transplantation (HSCT) market include AllCells Corp., Athersys Inc., Beike Biotechnology Co. Ltd., bluebird bio Inc., Cellular Biomedicine Group Inc., Gamida Cell Ltd., Lonza Group Ltd., MEDIPOST Co. Ltd., Merck KGaA, Mesoblast Ltd., Pluristem Therapeutics Inc., Sanofi SA, Sartorius CellGenix GmbH, ScienCell Research Laboratories, Inc., STEMCELL Technologies, Inc., Taiga Biotechnologies Inc., Takeda Pharmaceutical Co. Ltd., Talaris Therapeutics and Thermo Fisher Scientific.

Key Developments

In June 2023, Kindred Group plc, a company that offers online services, launched a new campaign with Matchis, the Dutch Centre for Stem Cell Donors, to generate more awareness for stem cell transplantation and the shortage of donors.

In January 2023, Jasper Therapeutics, Inc., announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has granted orphan drug designation to briquilimab (formerly known as JSP191), a monoclonal antibody targeting the CD117 (stem cell factor) receptor, for conditioning treatment prior to HCT. Previously, the U.S. Food and Drug Administration granted orphan drug designation to briquilimab in HCT, as well as rare pediatric disease designation for the treatment of severe combined immunodeficiency (SCID).

In June 2022, Veloxis Pharmaceuticals, a specialty pharmaceutical company, announced the dosing of the first patient by its partner, Xenikos B.V., a privately held biotechnology company, in a pivotal Phase 3 clinical study [NCT04934670] designed to evaluate T-Guard versus ruxolitinib for the treatment of patients with Grade III or IV steroid-refractory acute graft-versus-host disease (SR-aGVHD) following allogeneic hematopoietic stem cell transplant (allo-HSCT). T-Guard is currently being developed by Xenikos B.V.

Transplant Types Covered
• Allogeneic
• Autologous
• Other Transplant Types

Disease Indications Covered
• Lymphoproliferative Disorders
• Non-malignant Disorders
• Leukemia
• Other Disease Indications

Applications Covered
• Bone Marrow Transplant (BMT)
• Peripheral Blood Stem Cells Transplant (PBSCT)
• Cord Blood Transplant (CBT)
• Other Applications

End Users Covered
• Hospitals
• Specialty Clinics
• Other End Users

Regions Covered
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements